On April 4, 2025 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, reported that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025 (Press release, Renovorx, APR 4, 2025, View Source [SID1234651809]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Bagai will discuss recent corporate milestones, including an update on RenovoRx’s continued momentum of its RenovoCath commercial efforts, including new purchase orders and reorders received from cancer center customers, and the realization of initial revenues from RenovoCath sales.
Mr. Bagai will also discuss progress on RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluating RenovoRx’s lead drug-device combination product candidate (intra-arterial delivery of gemcitabine via the RenovoCath catheter, known as IAG) which uses the proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). This combination product candidate, IAG, which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and has not been approved for commercial sale.
Presentation Details:
Date: Thursday, April 10, 2025
Time: 3:30 p.m. ET
Webcast: View Source
To schedule a one-on-one investor meeting with Mr. Bagai, please contact your LD Micro representative or KCSA Strategic Communications at [email protected].